Traditionally, the only definitive therapy for patients who have advanced, medically refractory heart failure was replacement of the heart with another human heart. However, transplantation is an inadequate option in light of the large number of potential candidates, the lack of donors, and the coexisting conditions that make most potential candidates ineligible for transplantation. In this context, ventricular assist devices, or heart pumps, become an attractive option for patients who have advanced heart failure.
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Traditionally, the only definitive therapy for patients who have advanced, medically refractory heart failure was replacement of the heart with another human heart. However, transplantation is an inadequate option in light of the large number of potential candidates, the lack of donors, and the coexisting conditions that make most potential candidates ineligible for transplantation. In this context, ventricular assist devices, or heart pumps, become an attractive option for patients who have advanced heart failure.
Rather than replacing the human heart completely, ventricular assist devices serve in a true "assistance" capacity by supplementing the cardiac output of the native but weakened heart. The native heart is generally left in place, to serve as both a biologic conduit to fill the ventricular assist device and as a backup "pump." First-generation devices are pulsatiledisplacement pumps that provide blood flow in a fashion analogous to that in the native heart. Such pumps are limited by size and durability, since pulsatility necessitates the mechanical wear of the ventricular assist device. Continuous-flow pumps have small rotating impellers that propel blood forward with surprisingly little hematologic trauma and can do so with greater durability and a smaller size (about the size of a D battery) than pulsatile-flow devices, since there is only a single moving part. Newer pumps use bearing-free designs to minimize device wear. Power delivery still requires percutaneous, rather than transcutaneous, energy sources.
The concept of using a ventricular assist device as a permanent solution for end-stage heart failure was tested almost a decade ago. In the landmark Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) randomized trial (ClinicalTrials.gov number, NCT00000607 [ClinicalTrials.gov] ), 1 pulsatile-flow left ventricular assist devices dramatically reduced mortality, by 48%, in 129 patients who had severe heart failure and were not eligible for transplantation. Ventricular assist devices were subsequently approved for "destination therapy" by the Food and Drug Administration, in 2002, in large part because of the dramatic results of the REMATCH trial. Yet, the 1-year survival rate was still suboptimal in the patients who underwent placement of a ventricular assist device (52%, vs. 25% of the medically treated patients) and at 2 years (23% vs. 8%).
The study by Slaughter and colleagues 2 in this issue of the Journal (NCT00121485 [ClinicalTrials.gov] ) represents another important step in the use of left ventricular assist devices for refractory heart failure. A second-generation ventricular assist device, a continuous axial-flow pump, was used in the trial and was part of the original program that studied its use as a bridge to transplantation. 3 A total of 200 patients who had advanced heart failure and were ineligible for transplantation were randomly assigned, in a 2:1 ratio, to receive either the continuous-flow left ventricular assist device (134 patients) or the pulsatile-flow left ventricular assist device (66 patients). The primary end point was survival, at 2 years, free from disabling stroke and reoperation for device repair or replacement. Patients who had been assigned to receive the continuous-flow device fared better than those assigned to receive the pulsatile-flow device, with 46% and 11%, respectively, reaching the composite primary end point (hazard ratio, 0.38; 95% confidence interval [CI], 0.27 to 0.54; P<0.001). This finding was driven largely by the reduced need for device replacement in the continuous-flow group. One third of the pulsatileflow pumps required replacement over the 2-year study period (similar to the fraction in the REMATCH trial) as compared with only 10% of the continuous-flow pumps. The actuarial survival rate was significantly increased with the continuous-flow device (58%) as compared with the pulsatileflow device (24%) (P=0.008). The quality of life was improved to a similar degree in the two treatment groups. Adverse events -including sepsis, right heart failure, and repeat hospitalization -were less common with the continuous-flow pump.
What kind of patient was randomly assigned to a treatment group in the study by Slaughter and colleagues? As in the REMATCH trial, the patients were ill. High rates of inotropic support (79%) and low rates of use of angiotensin-converting-enzyme inhibitors (33%), angiotensin II-receptor antagonists (8%), and beta-blockers (55%) indicate the presence of severe disease. However, patients were selected carefully, with a mean destination therapy risk score 4 of 10, corresponding to a low-to-medium risk (predictive of a probability of survival to hospital discharge of more than 70%). Although transplantation ineligibility is often subjective, the most common reason cited was advanced age (although the patients were about 5 years younger than those in the REMATCH cohort).
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Several limitations in the trial by Slaughter and colleagues are worth noting. The number of patients who had undergone screening to permit the enrollment of the 200 patients who ultimately participated in the trial was not reported. It was not possible to make the investigators and patients unaware of the treatment assignments, since one device is more audible than the other, despite the similarity of their external components. This lack of blinding may have influenced the reporting of the adverse events, which generally showed a trend in favor of the continuous-flow pump. Finally, the postoperative mortality was not reported in either treatment group.
Stroke remains a major challenge with both pumps. The rate of disabling stroke (12%) did not differ significantly between the continuous-flow group and the pulsatile-flow group, despite the use of triple-drug antithrombotic therapy (warfarin, aspirin, and dipyridamole) in the continuous-flow group as compared with aspirin alone in the pulsatile-flow group. Although the rate of any stroke favored the continuous-flow device over the pulsatile-flow device (0.13 vs. 0.22 events per patient-year), this reduction was not significant (P=0.21). Rehospitalization was common, with almost all patients in both groups requiring at least one admission over the course of the trial, although patients with a continuous-flow device were hospitalized less than were patients with a pulsatile-flow device (hazard ratio, 0.62; 95% CI, 0.41 to 0.93; P=0.02). The functional capacity was similarly improved in both groups, as evidenced by a near-doubling of the 6-minute walk distance, improvement in symptoms corresponding to a reduction by one or two NYHA functional classes, and robust increases in quality-of-life scores.
What is truly remarkable is the significant improvement in the probability of survival associated with the continuous-flow device (Figure 1 ). The mean survival in the current study (2 years) is double that in the REMATCH trial (1 year). If one considers that the mean survival among patients receiving inotropic support alone is 6 months, the use of continuous-flow left ventricular assist devices appears to have quadrupled the survival of these patients in the past decade. How do we integrate the results of this study into clinical practice today? The first priority would be to make sure patients and physicians are aware that ventricular assist device therapy is available, effective, and safe for well-selected patients. Second, we should not delay referral until surgical morbidity and mortality become prohibitive. Lessons from clinical experience and published reports 5, 6 support the notion that the optimal time for referral is most likely before the development of major complications from heart failure. Any patient in whom intravenous inotropic support is required should be considered a candidate for destination therapy. Third, the evaluation and care of these patients requires special expertise. Identifying the optimal timing for implantation in an individual patient's course of progressive heart failure is an art and a science. The American Board of Internal Medicine's subspecialty of Advanced Heart Failure and Transplantation Cardiology and the Joint Commission's certification for destination therapy were created with this in mind.
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Philosophically, some view the use of a mechanical pump for heart failure as conceding the biologic battle; for others, it is a practical decision to refer a patient for left ventricular assist device therapy when contemporary therapies have been exhausted. Although the selection of patients, device durability and cost, and other considerations remain challenges in this rapidly evolving field, there is little doubt that left ventricular assist devices are viable and important options for patients with medically refractory advanced heart failure.
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